Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of February 19, 2026.

Business Wire • Feb 19, 2026

Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate pharma to participate in the Leerink Partners Global Healthcare Conference.

Business Wire • Feb 18, 2026

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of December 31, 2025: Total number of shares outstanding: 93,719,323 ordinary shares   6,3.

Business Wire • Jan 7, 2026

Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of December 18, 2025: Total number of shares outstanding:       92,197,823 ordinary shares.

Business Wire • Dec 22, 2025

Innate Pharma Releases Its 2026 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year financial statements November 5, 2026: Publication of revenue and cash position for 3Q2026 All financia.

Business Wire • Dec 11, 2025

Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of November 27, 2025.

Business Wire • Nov 28, 2025

Innate Pharma to Present at Jefferies Global Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)-- #Congress--Innate Pharma to present at Jefferies Global Healthcare Conference.

Business Wire • Nov 17, 2025

Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript

Innate Pharma S.A. ( IPHA ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Stephanie Cornen - Vice President of Investor Relations, Communication & Commercial Strategy Jonathan Dickinson - CEO & Director Sonia Quaratino - Executive VP & Chief Medical Officer Conference Call Participants Christopher Liu - Lucid Capital Markets, LLC, Research Division Justin Zelin - BTIG, LLC, Research Division Swayampakula Ramakanth - H.C.

Seeking Alpha • Nov 13, 2025

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2025. “This quarter highlights strong execution across our key programs,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “With FDA clearance to initiate TELLOMAK-3, we are advancing lacutamab toward its confirmatory Phase 3 and potential accelerated approval.

Business Wire • Nov 13, 2025

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed. The planned confirmatory Phase 3 trial, TELLOMAK 3, is an open-label, randomized study designed to demonstrate the efficacy of la.

Business Wire • Nov 10, 2025